1592 related articles for article (PubMed ID: 8426860)
21. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
[TBL] [Abstract][Full Text] [Related]
22. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
23. [Oral contraception and its beneficial gynecological effects].
Belaisch J; Hommais-loufrani B
Fertil Contracept Sex; 1988 Mar; 16(3 Suppl):3-7. PubMed ID: 12282188
[TBL] [Abstract][Full Text] [Related]
24. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
25. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
Papp C; Schatz F; Krikun G; Hausknecht V; Lockwood CJ
Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
[TBL] [Abstract][Full Text] [Related]
26. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen.
Lahti E; Blanco G; Kauppila A; Apaja-Sarkkinen M; Taskinen PJ; Laatikainen T
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):660-4. PubMed ID: 8469450
[TBL] [Abstract][Full Text] [Related]
27. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups.
Schlesinger C; Kamoi S; Ascher SM; Kendell M; Lage JM; Silverberg SG
Int J Gynecol Pathol; 1998 Oct; 17(4):302-11. PubMed ID: 9785130
[TBL] [Abstract][Full Text] [Related]
28. Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge.
Truskinovsky AM; Lifschitz-Mercer B; Czernobilsky B
Int J Gynecol Pathol; 2014 Mar; 33(2):107-13. PubMed ID: 24487463
[TBL] [Abstract][Full Text] [Related]
29. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium.
Afify AM; Craig S; Paulino AF; Stern R
Ann Diagn Pathol; 2005 Dec; 9(6):312-8. PubMed ID: 16308159
[TBL] [Abstract][Full Text] [Related]
30. [The endometrium under the effects of hormone replacement therapy in menopause with percutaneous estradiol and low-dose micronized progesterone].
Philippe E; Faguer B; Engelman A; Charpin C; Loubière R; de Mascarel A; Leduc F; Dupin P; Hemet J; Vauzelle JL
Pathologica; 1993; 85(1099):475-87. PubMed ID: 8127629
[TBL] [Abstract][Full Text] [Related]
31. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
Boruban MC; Altundag K; Kilic GS; Blankstein J
Eur J Cancer Prev; 2008 Apr; 17(2):133-8. PubMed ID: 18287870
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
33. [The present state of research on the relationship of oral contraceptives to breast cancer].
Pike MC
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):329-38. PubMed ID: 12280203
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT.
Dahmoun M; Odmark IS; Risberg B; Karlsson MG; Pavlenko T; Bäckström T
Maturitas; 2004 Oct; 49(2):114-23. PubMed ID: 15474755
[TBL] [Abstract][Full Text] [Related]
35. Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
Gibbons WE; Thorneycroft IH
J Reprod Med; 1999 Feb; 44(2 Suppl):203-8. PubMed ID: 11392033
[TBL] [Abstract][Full Text] [Related]
36. The pill and the breast.
Drife JO
IPPF Med Bull; 1984 Dec; 18(6):1-2. PubMed ID: 12313402
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action.
Gold LI; Saxena B; Mittal KR; Marmor M; Goswami S; Nactigal L; Korc M; Demopoulos RI
Cancer Res; 1994 May; 54(9):2347-58. PubMed ID: 8162580
[TBL] [Abstract][Full Text] [Related]
38. [Morphologic endometrium changes with tamoxifen].
Dallenbach-Hellweg G; Hahn U; Schmidt D
Zentralbl Gynakol; 1996; 118(6):365-9. PubMed ID: 8768015
[TBL] [Abstract][Full Text] [Related]
39. [Idiopathic endometrial decidual reaction in a woman in postmenopause: immunocytochemical evaluation of estrogen and progesterone receptors and its corticoid binding globulin].
Vasconcellos A; Villagrán E; Peña P; Miska W; Sánchez R
Rev Med Chil; 2002 Apr; 130(4):425-9. PubMed ID: 12090108
[TBL] [Abstract][Full Text] [Related]
40. [Precancerous lesion of the endometrium and endometrial morphology in patients with tamoxifen therapy].
Schmidt D; Horn LC
Zentralbl Gynakol; 2002 Jan; 124(1):3-9. PubMed ID: 11873307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
